Severe asthma is a heterogeneous disease, which, as it is now believed, requires a personalized therapy dependent on phenotype. Omalizumab, a humanized monoclonal antibody that specifically binds to free immunoglobulin E, proved to be particularly effective in the treatment of allergic asthma. Because this treatment is very expensive, in Poland it is reimbursed under the drug program: “Omalizumab treatment of severe, allergic, IgE-dependent asthma”. One of the main features of drug programs is precise defining the group of patients, which may be subject to treatment. The current experience shows that it significantly increase the efficacy of the therapy. On the other hand, however, may adversely affect the possibility of treating patients with difficult access to specialized centres.